Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-24.84% $0.0941
America/New_York / 25 jul 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2.64 mill |
EPS: | -0.840 |
P/E: | -0.112 |
Earnings Date: | Aug 08, 2023 |
SharesOutstanding: | 28.02 mill |
Avg Daily Volume: | 1.037 mill |
RATING 2023-08-21 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Neutral | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.112 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.02x |
Company: PE -0.112 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ -0.0470 - 0.159 ( +/- 183.93%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-27 | Sanders Machelle | Sell | 11 553 | Common Stock |
2023-06-06 | John A. Donofrio | Buy | 85 000 | Restricted Stock Units |
2023-06-06 | Gay John M. | Buy | 200 000 | Restricted Stock Units |
2023-06-07 | Gay John M. | Buy | 65 000 | Common Stock |
2023-06-06 | Gay John M. | Buy | 65 000 | Restricted Stock Units |
INSIDER POWER |
---|
60.98 |
Last 97 transactions |
Buy: 4 746 863 | Sell: 340 227 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.0941 (-24.84% ) |
Volume | 6.93 mill |
Avg. Vol. | 1.037 mill |
% of Avg. Vol | 668.48 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.